News
Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE ® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback